Verastem Oncology is debuting a digital campaign to help people understand the differences in low-grade serous ovarian cancer.
Verastem's new campaign aims to make distinctions in rare type of ovarian cancer
When Tiffany Stout was first diagnosed with ovarian cancer in 2015, she didn’t immediately take in the fact that it was specifically the low-grade serous type. It wasn’t until she met with her doctor later and understood she had low-grade serous ovarian cancer (LGSOC), a rare disease that grows more slowly than the more common high-grade serous type, but that is also resistant to chemotherapy and highly recurrent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
